60
Participants
Start Date
September 29, 2025
Primary Completion Date
January 31, 2027
Study Completion Date
June 30, 2027
fruquintinib
Participants will receive oral fruquintinib, with or without food, for the first 21 days of each 28-day cycle.
FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Participants will receive FOLFIRI once every 2 weeks on day 1 of every 28-day cycle (twice in each cycle). The FOLFIRI regimen consists of irinotecan given 180 mg/m2 intravenous infusion (IV), leucovorin 400 mg/m2 (or 200 mg/m2 levoleucovorin) IV, followed by 5-fluorouracil (5-FU) 400 mg/m2 bolus injection and 5-FU continuous IV infusion of 2400 mg/m2 over 46 to 48 hours.
RECRUITING
Maryland Oncology Hematology, Columbia
RECRUITING
Blue Ridge Cancer Care (Oncology & Hematology Associates of Southwest VA), Salem
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
Minnesota Oncology Hematology - Primary, Maple Grove
RECRUITING
Texas Oncology - Northeast Texas, Tyler
RECRUITING
Texas Oncology - Gulf Coast, Beaumont
RECRUITING
Texas Oncology - Central/South Texas, Austin
RECRUITING
Rocky Mountain Cancer Center - Primary, Denver
RECRUITING
Northwest Cancer Specialists - Compass, Portland
RECRUITING
Oncology Associates of Oregon - Primary, Eugene
Takeda Development Center Americas, Inc.
INDUSTRY
SCRI Development Innovations, LLC
OTHER